Welcome to our dedicated page for MyMD Pharmaceuticals news (Ticker: MYMD), a resource for investors and traders seeking the latest updates and insights on MyMD Pharmaceuticals stock.
MyMD Pharmaceuticals, Inc. (DE) (NASDAQ: MYMD) is a clinical-stage biopharmaceutical company that focuses on extending healthy lifespan through the development of innovative therapeutic platforms. The company is committed to addressing serious autoimmune and inflammatory diseases as well as age-related conditions.
Core Therapeutic Platforms:
- MyMD-1: This is a small molecule drug platform that aims to regulate the immunometabolic system by controlling tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines. MyMD-1 is being developed to treat autoimmune diseases such as multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. Additionally, it targets age-related illnesses, including frailty and sarcopenia. The drug’s oral administration is a significant advantage over existing TNF-α inhibitors, which require injectable forms.
- Supera-CBD: This drug platform is based on a novel synthetic derivative of cannabidiol (CBD) that targets key receptors, including CB2 and opioid receptors, and inhibits monoamine oxidase. Supera-CBD is designed to cater to the rapidly expanding CBD market, addressing conditions such as epilepsy, pain, and anxiety/depression.
Recent Achievements and Current Projects:
MyMD Pharmaceuticals has made significant strides in its clinical trials, particularly with MyMD-1. In a recently completed phase 2 clinical trial, MyMD-1 successfully met its primary endpoints by reducing biomarkers common in chronic inflammatory diseases, such as TNF-α, IL-6, and sTNFR1. The drug also met all secondary endpoints related to safety and tolerability standards. Full study results are expected to be released in 2024.
The company has already submitted and received approval for three Investigational New Drug Applications for MyMD-1, which is now advancing in clinical programs for conditions like sarcopenia, rheumatoid arthritis, and Hashimoto's disease. With a unique oral dosing method, MyMD-1 offers a promising alternative to current TNF-α inhibitors, which typically require infusion or injection.
Partnerships and Future Outlook:
Through strategic partnerships and ongoing research, MyMD Pharmaceuticals aims to pioneer the development of therapies that not only manage symptoms but also extend the healthy lifespan of patients. With its robust pipeline and innovative approaches, MyMD Pharmaceuticals is well-positioned to make a significant impact in the field of autoimmune and age-related disease treatment.
For up-to-date news and developments, visit the StockTitan website.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced a securities purchase agreement to raise approximately $15 million in convertible preferred stock and warrants, expected to close on February 23, 2023. This financing will support the development of MYMD-1 for sarcopenia and rheumatoid arthritis. The preferred stock has a conversion price of $2.255 per share, a 10% premium to the closing share price on February 17, 2023. The offering is made under a previously filed shelf registration statement. MyMD aims to advance its clinical trials while continuing to explore MYMD-1’s applications in autoimmune diseases.
MyMD Pharmaceuticals (Nasdaq: MYMD) presented data at the 2022 British Society for Immunology Congress, highlighting MYMD-1®, a selective TNF-α inhibitor. Preclinical studies demonstrated a 37% reduction in inflammation in a mouse model compared to 29% by etanercept (Enbrel®). Clinical trials showed MYMD-1 was safe and well-tolerated at various doses. With its oral administration and ability to cross the blood-brain barrier, MYMD-1 may offer a new treatment avenue for rheumatoid arthritis and other autoimmune diseases.
MyMD Pharmaceuticals (Nasdaq: MYMD) is set to present late-breaking data on its drug candidate, MYMD-1, at the 2022 British Society for Immunology Congress in Liverpool, England, on December 6, 2022, at 6pm GMT. This oral TNF-α inhibitor shows promise in treating autoimmune diseases and may transform treatment strategies for conditions like rheumatoid arthritis. MYMD-1 is notable for its ability to orally administer therapy, crossing the blood-brain barrier while maintaining anti-inflammatory effects without immunosuppression.
MyMD Pharmaceuticals (NASDAQ: MYMD) announced the publication of positive results from a Phase 1 study of MYMD-1, an oral TNF-α inhibitor, in the journal Drug Research. The study demonstrated a favorable safety and tolerability profile without clinically relevant adverse events for single daily doses up to 450 mg and multiple daily doses of 600 mg. MYMD-1's oral formulation presents a significant advancement for treating autoimmune diseases, with ongoing Phase 2 trials for sarcopenia and plans to evaluate it for rheumatoid arthritis. Results are anticipated in Q4 2022.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced progress in its Phase 2 clinical trial for MYMD-1®, an oral TNF-alpha inhibitor targeting chronic inflammation from sarcopenia and frailty. The trial has completed dosing for the second patient cohort, with no safety or toxicity issues reported. The Safety Review Committee unanimously approved escalating to the next dose, and enrollment for the next cohort will begin. Efficacy data is anticipated in Q4 2022.
MyMD Pharmaceuticals announced the European Patent Office's decision to grant patent claims for its Supera-CBD™ compound, recognizing it as a new molecular entity. This development demonstrates Supera-CBD™'s potential in treating pain and anxiety by selectively binding to the CB2 receptor. The ongoing clinical trial for MYMD-1, an oral TNF-α inhibitor aimed at reducing chronic inflammation, adds to MyMD's advancements in drug development, with positive progress noted in the trial's dosing. The company’s patent portfolio continues to expand globally.
MyMD Pharmaceuticals (MYMD) announced the publication of a pre-clinical study of its oral TNF-α inhibitor, MYMD-1, in the Journal of Gerontology. The study showed that MYMD-1 significantly outperformed rapamycin, demonstrating four-fold better results in delaying aging and extending lifespan in mice treated at the equivalent of 60 human years. The research indicated improvements in health span characteristics, including muscle strength and reduced frailty progression. MYMD-1 is currently in a Phase 2 study targeting sarcopenia and frailty.
MyMD Pharmaceuticals has announced progress in its Phase 2 clinical trial for MYMD-1, targeting aging-related sarcopenia. Patient enrollment for the next dose has begun after the Safety Review Committee confirmed no safety issues in the prior cohort. The trial aims to demonstrate reduced levels of TNF-alpha in patients aged 65 and over. The market opportunity is significant, with potential revenues exceeding
MyMD Pharmaceuticals has entered into a material transfer agreement with Bascom Palmer Eye Institute to explore the use of MYMD-1 in treating traumatic optic neuropathy (TON). TON affects vision due to optic nerve injury, occurring in 1.5% to 4% of head trauma cases. The study is fully funded by Bascom Palmer, ranked #1 eye hospital in the U.S. for 20 consecutive years. MyMD’s MYMD-1, originally developed for autoimmune diseases, is positioned as a potential treatment for various conditions due to its novel mechanism.
MyMD Pharmaceuticals (NASDAQ: MYMD) announced progress in its Phase 2 clinical trial for MYMD-1, aimed at delaying aging and chronic inflammation in individuals over 65. All trial sites are now actively enrolling patients, with efficacy data anticipated in the second half of 2022. Previous Phase 1 results indicated a significant decrease in TNF-alpha levels in treated subjects. The aging treatment market is projected to exceed $600 billion by 2025, with no other FDA-approved drugs targeting aging disorders currently available.
FAQ
What is the current stock price of MyMD Pharmaceuticals (MYMD)?
What is the market cap of MyMD Pharmaceuticals (MYMD)?
What is MyMD Pharmaceuticals, Inc.?
What are the main therapeutic platforms developed by MyMD Pharmaceuticals?
What is MyMD-1?
What is Supera-CBD?
What recent achievements has MyMD Pharmaceuticals made?
What conditions is MyMD-1 being developed to treat?
How is MyMD-1 administered?
What are the potential benefits of Supera-CBD?
Has MyMD Pharmaceuticals received any regulatory approvals?
What is the future outlook for MyMD Pharmaceuticals?
